Psychedelic Invest’s very own Adam Tubero digs into Mind Medicine’s ($MNMD) LSD program, Ibogaine, and the company’s Q1 2022 earnings report. Adam explains why his sentiment around MNMD has started to shift lately. Are you bullish or bearish? Leave your comments over on the Psychedelic Invest YouTube channel.

You must have PRO to access this content.

Become a Pro
Login with Neuly